References
- Auclair C, Kelly PA, Coy DH, Schally AV, Labrie F. Potent inhibitory activity of (D-Leu6, des-Gly-NH210) LHRH ethylamide on LH/hCG and PRL testicular receptor levels in the rat. Endocrinology 1977; 101: 1890–1893
- Auclair C, Kelly PA, Labrie F, Coy DH, Schally AV. Inhibition of testicular luteinizing hormone receptor level by treatment with a potent luteinizing hormone-releasing hormone agonist or human chorionic gonadotropin. Biochem Biophys Res Commun 1977; 76: 855–862
- Castro AE, Seiguer AC, Mancini RE. Electron microscopic study of the localization of labelled gonadotropins in the Sertoli and Leydig cells of the rat testis. Proc Soc Exp Biol Med 1970; 133: 582–586
- Catt KJ, Dufau ML, Tsuruhara T. Studies on a radioligand-receptor assay system for luteinizing hormone and chorionic gonadotropin. J Clin Endocrinol Metab 1971; 32: 860–863
- Cusan L, Auclair C, Belanger A, Ferland L, Kelly PA, Seguin C, Labrie F. Inhibitory effects of long-term treatment with a luteinizing hormone-releasing hormone agonist on the pituitary-gonadal axis in male and female rats. Endocrinology 1979; 104: 1369–1376
- Day RV. Male sex hormone therapy. J Urol 1939; 41: 210–219
- Frowein J, Engel W. Constitutivity of the hCG-receptor protein in the testis of rat and man. Nature 1974; 249: 377–379
- Gavin JR, Roth J, Neville DM, DeMeyts P, Buell DN. Insulin-dependent regulation of insulin receptor concentrations. A direct demonstration in cell culture. Proc Natl Acad Sci USA 1974; 71: 84–88
- Geller J, Bora R, Roberts T, Newman H, Lin A, Silva R. Treatment of benign prostatic hypertrophy with hydroxyprogesterone caproate. JAMA 1965; 193: 115–122
- Hinkle PM, Tashjian HH. Thyrotropin-releasing hormone regulates the number of its own receptors in the GH3 strain of pituitary cells in culture. Biochemistry 1975; 14: 3845–3851
- Hsueh AJW, Dufau ML, Catt KJ. Gonadotropin-induced regulation of luteinizing hormone receptors and desensitization of testicular 3′:5′-cyclic AMP and testosterone responses. Proc Natl Acad Sci USA 1977; 74: 592–595
- Huggins C, Stevens RA. The effect of castration on benign hypertrophy of the prostate in man. J Urol 1940; 43: 705–714
- Johnson ES, Seeley JH, White WF, DeSombre ER. Endocrine-dependent rat mammary tumor regression: use of a gonadotropin releasing hormone analog. Science 1976; 194: 329–330
- Kaufman JJ, Goodwin WE. Hormonal management of the benign obstructing prostate: use of combined androgen-estrogen therapy. J Urol 1959; 81: 165–171
- Kledzik GS, Cusan L, Auclair C, Kelly PA, Labrie F. Inhibition of ovarian luteinizing hormone (LH) and follicle-stimulating hormone receptor levels with an LH-releasing hormone agonist during the estrous cycle in the rat. Fertil Steril 1978; 30: 348–353
- Lesniak MA, Roth J. Regulation of receptor concentration by homologous hormone. Effect of human growth hormone on its receptor in IM-9 lymphocytes. J Biol Chem 1976; 251: 3720–3729
- Mukherjee C, Caron MG, Lefkowitz RJ. Cathecholamine-induced subsensitivity of adenylate cyclase associated with loss of β-adrenergic receptor binding sites. Proc Natl Acad Sci USA 1975; 72: 1945–1949
- Peirson EL. A study of the effect of stilbestrol therapy on the size of the benignly hypertrophied prostate gland. J Urol 1946; 55: 73–78
- Rajaniemi H, Vanha-Perttula T. Specific receptor for LH in the ovary: evidence by autoradiography and tissue fractionation. Endocrinology 1972; 90: 1–9
- Tsuruhara T, Dufau ML, Cigorraga S, Catt KJ. Hormonal regulation of testicular luteinizing hormone receptors. Effects on cyclic AMP and testosterone responses in isolated Leydig cells. J Biol Chem 1977; 252: 9002–9009